Home » Posts tagged with » IBRANCE
IBRANCE fails to meet primary endpoint in early breast cancer trial

IBRANCE fails to meet primary endpoint in early breast cancer trial

Pfizer said that the phase 3 PENELOPE-B clinical trial of IBRANCE (palbociclib) in early breast cancer failed to meet its primary endpoint. The collaborative late-stage trial is being held by the US pharma giant with the German Breast Group (GBG) sponsoring it. The primary endpoint of the PENELOPE-B clinical trial is improved invasive disease-free survival […]